The global smart inhalers market size was valued at USD 34 million in 2018 and is estimated to reach USD 1,406 million by 2026, growing at a CAGR of 58.4% from 2019 to 2026
Smart inhalers are the devices that are used for delivering a variety of medication through inhalation. The drugs used in the inhalers include anti-cholinergic, glucocorticoids, insulin, and beta-agonists for the treatment and prevention of respiratory diseases such as asthma and chronic obstructive pulmonary diseases. These inhalers are termed smart inhalers, owing to the sensors attached as a clip on to the inhalers monitoring the right dose per intake and the technique used for inhaling the medication. The data acquired by the sensor is shared with the patient and healthcare professionals to track their inhaler usage. The data monitored is then shared using the Bluetooth technology to their mobile apps through a platform such as Hailie. Hailie systems is a type of sensors that is attached to the inhaler and shares the data through the operating platform for tracking their health and adherence rate.
Smart inhalers have proved to increase the adherence rate in patients suffering from asthma and COPD. Moreover, the smart inhalers also help in monitoring the technique used for inhaling the medicine in an effective manner as compared to the normal inhalers. Smart Inhalers are of two types, such as metered dose inhalers and dry powder inhalers.
Recent developments include collaboration between Novartis and Qualcomm, acquisition of Inspiro Medical by Opko Health, and acquisition of Gecko Health by Teva Pharmaceuticals for manufacturing smart inhalers. These developments aim to manufacture smart inhalers as well as devices with inbuilt smart inhalers, which will positively increase the market revenue soon and competition among the manufacturers will increase. Thus, smart inhalers is a very lucrative market and is expected to provide multiple opportunities for both the consumers as well as manufacturers.
The global smart inhalers market is driven by increased prevalence of people suffering from asthma and chronic obstructive pulmonary diseases, and technological advancements in the development of better smart inhaler devices and systems. Furthermore, untapped market potential in developing regions with more population and lack of healthcare amenities is expected to provide lucrative opportunities for smart inhalers market trends. However, higher cost associated with the development of smart inhalers for asthma and COPD is expected to restrain the smart inhalers market growth, owing to its unaffordability in the developing nations as opposed to the normal inhalers.
Based on product, the smart inhalers market is segmented into inhalers and nebulizers. Inhalers can be further bifurcated into metered dose inhalers and dry powder inhalers. Metered dose inhalers maintain the amount of dosage used per inhalation for medication whereas dry powder inhalers deliver medications such as corticosteroids directly to the lungs and is breath activated.
By indication, the asthma segment accounted for the highest share in 2018, owing to rise in prevalence of people suffering from respiratory diseases such as bronchitis, asthma, and other chronic obstructive pulmonary diseases. Whereas COPD is expected to be the fastest growing segment during the forecast period that would largely affect the smart inhalers market growth, the high CAGR rate can be attributed to rise in incidence of COPD in the population worldwide and increased adoption of smart inhalers for better treatment of the respiratory diseases. Moreover, the factors contributing toward the adoption of smart inhalers as compared to normal inhalers include better adherence to the medication and monitoring of the dosage used per intake.
Based on regional presence, the global smart inhalers market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the leading region for the global smart inhalers market due to better healthcare infrastructure and facilities, prevalence in the number of patient suffering from asthma and chronic obstructive pulmonary diseases, and increase in geriatric population. Emerging market such as LAMEA is expected to experience delayed growth, owing to poor infrastructure and healthcare facilities along with lack of awareness among the population. As smart inhalers technology is still in its nascent stage and many start-ups and pharmaceutical companies are developing the smart inhaler technology that could bring to the patient population at lower cost. The huge investment for the development of smart inhalers has propelled the growth of the global smart inhalers market, which is expected to follow the trend throughout the forecast period.
Some of the key manufacturers of global smart inhalers market include Adherium, AstraZeneca, Boehringer Ingelheim, Cohero Health, Glaxo Smith Kline, Novartis International AG, Opko Health, ResMed, Inc., Teva Pharmaceutical Industries Limited, and Vectura Group plc.
This report entails the global smart inhalers market analysis along with the current trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment. The global smart inhalers market size and estimations are based on a comprehensive analysis of key developments in the industry. A qualitative analysis of global smart inhalers market share based on innovative products facilitates strategic business planning.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Research methodology
1.2.1. Secondary research
1.2.2. Primary research
1.2.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings
2.1.1. Top investment pockets
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key forces shaping smart Inhalers market
3.2.1. Moderate bargaining power of suppliers
3.2.2. High bargaining power of buyers
3.2.3. High threat of new entrants
3.2.4. Moderate threat of substitutes
3.2.5. High intensity of rivalry
3.3. Value Chain Analysis
3.5. Industry pain point analysis
3.6. Patent Analysis
3.7. Market share analysis
3.8. Market Dynamics
3.8.1. Drivers
3.8.1.1. Increase in Air Pollution
3.8.1.2. Increase In Population Susceptible To Indoor Air Pollutants
3.8.1.3. Increasing Prevalence Of COPD and Asthma ly
3.8.2. Restraints
3.8.2.1. Misusing Data And Data Privacy
3.8.2.2. Overall High Cost Of Asthma And COPD Treatment
3.8.3. Opportunities
3.8.3.1. Increased Focus Towards Advanced Treatment Protocols
CHAPTER 4: SMART INHALERS MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Inhalers
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast
4.2.3. Market analysis, by country
4.2.3.1. Dry Powder Inhalers
4.2.3.2. Metered Dose Inhalers
4.3. Nebulizers
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
CHAPTER 5: SMART INHALERS MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Asthma
5.2.1. Market size and forecast
5.2.2. Market analysis, by country
5.3. COPD
5.3.1. Market size and Forecast
5.3.2. Market analysis, by country
CHAPTER 6: SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Retail Pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online Pharmacies
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: SMART INHALERS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. North America market size and forecast, by product type
7.2.3. North America market size and forecast, by indication
7.2.4. North America market size and forecast, by distribution channel
7.2.6. North America market size and forecast, by country
7.2.6.1. U.S. market size and forecast, by product type
7.2.6.2. U.S. market size and forecast, by indication
7.2.6.3. U.S. market size and forecast, by distribution channel
7.2.6.5. Canada market size and forecast, by product type
7.2.6.6. Canada market size and forecast, by indication
7.2.6.7. Canada market size and forecast, by distribution channel
7.2.6.8. Mexico market size and forecast, by product type
7.2.6.9. Mexico market size and forecast, by indication
7.2.6.10. Mexico market size and forecast, by distribution channel
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Europe market size and forecast, by product type
7.3.3. Europe market size and forecast, by indication
7.3.4. Europe market size and forecast, by distribution channel
7.3.5. Europe market size and forecast, by country
7.3.5.1. Germany market size and forecast, by product type
7.3.5.2. Germany market size and forecast, by indication
7.3.5.3. Germany market size and forecast, by distribution channel
7.3.5.4. France market size and forecast, by product type
7.3.5.5. France market size and forecast, by indication
7.3.5.6. France market size and forecast, by distribution channel
7.3.5.8. UK market size and forecast, by product type
7.3.5.9. UK market size and forecast, by indication
7.3.5.10. UK market size and forecast, by distribution channel
7.3.5.11. Italy market size and forecast, by product type
7.3.5.12. Italy market size and forecast, by indication
7.3.5.13. Italy market size and forecast, by distribution channel
7.3.5.14. Spain market size and forecast, by product type
7.3.5.15. Spain market size and forecast, by indication
7.3.5.16. Spain market size and forecast, by distribution channel
7.3.5.17. Rest of Europe market size and forecast, by product type
7.3.5.18. Rest of Europe market size and forecast, by indication
7.3.5.19. Rest of Europe market size and forecast, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Asia-Pacific market size and forecast, by product type
7.4.3. Asia-Pacific market size and forecast, by indication
7.4.4. Asia-Pacific market size and forecast, by distribution channel
7.4.5. Asia-Pacific market size and forecast, by country
7.4.5.1. Japan market size and forecast, by product type
7.4.5.2. Japan market size and forecast, by indication
7.4.5.3. Japan market size and forecast, by distribution channel
7.4.5.4. China market size and forecast, by product type
7.4.5.5. China market size and forecast, by indication
7.4.5.6. China market size and forecast, by distribution channel
7.4.5.7. India market size and forecast, by product type
7.4.5.8. India market size and forecast, by indication
7.4.5.9. India market size and forecast, by distribution channel
7.4.5.10. Australia market size and forecast, by product type
7.4.5.11. Australia market size and forecast, by indication
7.4.5.12. Australia market size and forecast, by distribution channel
7.4.5.13. Rest of Asia-Pacific market size and forecast, by product type
7.4.5.14. Rest of Asia-Pacific market size and forecast, by indication
7.4.5.15. Rest of Asia-Pacific market size and forecast, by distribution channel
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. LAMEA market size and forecast, by product type
7.5.3. LAMEA market size and forecast, by indication
7.5.4. LAMEA market size and forecast, by distribution channel
7.5.5. LAMEA market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by product type
7.5.5.2. Brazil market size and forecast, by indication
7.5.5.3. Brazil market size and forecast, by distribution channel
7.5.5.4. South Africa market size and forecast, by product type
7.5.5.5. South Africa market size and forecast, by indication
7.5.5.6. South Africa market size and forecast, by distribution channel
7.5.5.7. Rest of LAMEA market size and forecast, by product type
7.5.5.8. Rest of LAMEA market size and forecast, by indication
7.5.5.9. Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. Adherium Limited
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. AstraZeneca PLC
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Boehringer Ingelheim group
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. Cohero Health, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. GlaxoSmithKline plc
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. Novartis International AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. OPKO Health, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. ResMed Inc. (Propeller Health)
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Teva Pharmaceutical Industries Limited
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Vectura Group plc
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
TABLE 01. SMART INHALERS MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 02. SMART INHALERS MARKET FOR INHALERS, BY REGION, 2018–2026 ($MILLION)
TABLE 03. SMART INHALERS MARKET FOR NEBULIZERS, BY REGION, 2018–2026 ($MILLION)
TABLE 04. SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 05. SMART INHALERS MARKET FOR , BY REGION, 2018–2026, ($MILLION)
TABLE 06. SMART INHALERS MARKET FOR COPD, BY REGION, 2018–2026, ($MILLION)
TABLE 07. SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 08. SMART INHALERS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2018–2026, ($MILLION)
TABLE 09. SMART INHALERS MARKET RETAIL PHARMACIES, BY REGION, 2018–2026, ($MILLION)
TABLE 10. SMART INHALERS MARKET ONLINE PHARMACIES, BY REGION, 2018–2026, ($MILLION)
TABLE 11. SMART INHALERS MARKET, BY REGION, 2018–2026, ($MILLION)
TABLE 12. NORTH AMERICA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 13. NORTH AMERICA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 14. NORTH AMERICA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 15. NORTH AMERICA SMART INHALERS MARKET, BY COUNTRY 2018–2026, ($MILLION)
TABLE 16. U.S. SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 17. U.S. SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 18. U.S. SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 19. CANADA SMART INHALERS MARKET, BY PRODUCT TYPE2018–2026, ($MILLION)
TABLE 20. CANADA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 21. CANADA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 22. MEXICO SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 23. MEXICO SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 24. MEXICO SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 25. EUROPE SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 26. EUROPE SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 27. EUROPE SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 28. EUROPE SMART INHALERS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 29. GERMANY SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 30. GERMANY SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 31. GERMANY SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 32. FRANCE SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 33. FRANCE SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 34. FRANCE SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 35. UK SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 36. UK SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 37. UK SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 38. ITALY SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 39. ITALY SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 40. ITALY SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 41. SPAIN SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 42. SPAIN SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 43. SPAIN SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 44. REST OF EUROPE SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 45. REST OF EUROPE SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 46. REST OF EUROPE SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 47. ASIA-PACIFIC SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 48. ASIA-PACIFIC SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 49. ASIA-PACIFIC SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 50. ASIA-PACIFIC SMART INHALERS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 51. JAPAN SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 52. JAPAN SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 53. JAPAN SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 54. CHINA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 55. CHINA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 56. CHINA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 57. INDIA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 58. INDIA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 59. INDIA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 60. AUSTRALIA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 61. AUSTRALIA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 62. AUSTRALIA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 63. REST OF ASIA-PACIFIC SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 64. REST OF ASIA-PACIFIC SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 66. LAMEA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 67. LAMEA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 68. LAMEA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 69. LAMEA SMART INHALERS MARKET, BY COUNTRY, 2018–2026, ($MILLION)
TABLE 70. BRAZIL SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 71. BRAZIL SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 72. BRAZIL SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 73. SOUTH AFRICA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 74. SOUTH AFRICA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 75. SOUTH AFRICA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 76. REST OF LAMEA SMART INHALERS MARKET, BY PRODUCT TYPE, 2018–2026, ($MILLION)
TABLE 77. REST OF LAMEA SMART INHALERS MARKET, BY INDICATION, 2018–2026, ($MILLION)
TABLE 78. REST OF LAMEA SMART INHALERS MARKET, BY DISTRIBUTION CHANNEL, 2018–2026, ($MILLION)
TABLE 79. ADHERIUM: COMPANY SNAPSHOT
TABLE 80. ADHERIUM: OPERATING SEGMENTS
TABLE 81. ADHERIUM: PRODUCT PORTFOLIO
TABLE 82. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 83. ASTRAZENECA: OPERATING SEGMENTS
TABLE 84. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 85. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 86. BOEHRINGER INGELHEIM: OPERATING SEGMENTS
TABLE 87. COHERO HEALTH: COMPANY SNAPSHOT
TABLE 88. COHERO HEALTH: PRODUCT PORTFOLIO
TABLE 89. GSK: COMPANY SNAPSHOT
TABLE 90. GSK: OPERATING SEGMENTS
TABLE 91. NOVARTIS: COMPANY SNAPSHOT
TABLE 92. NOVARTIS: OPERATING SEGMENTS
TABLE 93. NOVARTIS: PRODUCT PORTFOLIO
TABLE 94. OPKO HEALTH: COMPANY SNAPSHOT
TABLE 95. OPKO HEALTH: OPERATING SEGMENTS
TABLE 96. OPKO HEALTH: PRODUCT PORTFOLIO
TABLE 97. RESMED: COMPANY SNAPSHOT
TABLE 98. RESMED: OPERATING SEGMENTS
TABLE 99. RESMED: PRODUCT PORTFOLIO
TABLE 100. TEVA: COMPANY SNAPSHOT
TABLE 101. TEVA: OPERATING SEGMENTS
TABLE 102. TEVA: PRODUCT PORTFOLIO
TABLE 103. VECTURA: COMPANY SNAPSHOT
TABLE 104. VECTURA: OPERATING SEGMENTS
TABLE 105. VECTURA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. TOP INVESTMENT POCKETS, 2019
FIGURE 02. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. LOW THREAT OF NEW ENTRANTS
FIGURE 05. MODERATE THREAT OF SUBSTITUTES
FIGURE 06. MODERATE INTENSITY OF RIVALRY
FIGURE 07. VALUE CHAIN ANALYSIS
FIGURE 08. INDUSTRY PAIN POINT ANALYSIS
FIGURE 09. SMART INHALERS DEVICES AND CONSUMABLES: MARKET SHARE ANALYSIS, 2018
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR DEVICES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR CONSUMABLES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR HOSPITALS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR COPD, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF SMART INHALERS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. ADHERIUM: NET SALES, 2016–2018 ($MILLION)
FIGURE 18. ADHERIUM: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 19. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 20. ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 21. ASTRAZENECA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 22. BOEHRINGER INGELHEIM: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 24. BOEHRINGER INGELHEIM: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 25. GSK: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. GSK: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 28. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 29. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 31. OPKO HEALTH: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. OPKO HEALTH: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33. OPKO HEALTH: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 34. RESMED: NET SALES, 2016–2018 ($MILLION)
FIGURE 35. RESMED: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 36. TEVA: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. TEVA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. VECTURA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. VECTURA: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
$5769
$6450
$8995
Add to Cart
Add to Cart
Add to Cart
Add to Cart